Are 3 Antiplatelet Agents Better Than 1 or 2 for Recurrent Stroke Prevention?

February 28, 2018

Information sourced from NEJM Journal Watch:

 

Are Three Antiplatelet Agents Better Than One or Two for Recurrent Stroke Prevention?

 

Not in patients with a recent stroke or TIA, new findings demonstrate.

 

For the approximately 80% of patients with ischemic stroke or transient ischemic attack (TIA) without cardiac embolism antiplatelet therapy is recommended for future stroke prevention. Guidelines recommend aspirin monotherapy, clopidogrel monotherapy, or aspirin plus extended release dipyridamole (DP). To determine whether three antiplatelet agents used simultaneously provides greater protection than standard treatment, researchers randomized 3096 patients (mean age, 69; 63% men) from four countries over a 7-year period to “triple therapy” (usually 75 mg aspirin, 75 mg clopidogrel, and 400 mg DP daily) or standard therapy (clopidogrel monotherapy or aspirin plus DP). Patients qualified with an ischemic stroke (72% of the cohort) or TIA in the preceding 48 hours, and treatments were continued for 30 days. The primary endpoint was stroke or TIA during a 90-day follow-up period, assessed by central telephone calls.

 

The trial was stopped for futility. The two groups did not differ significantly in the primary outcome (stroke/TIA rate, 6% triple therapy, 7% standard therapy). Triple-therapy patients had a 2.5 times higher risk for bleeding, including a higher rate of fatal/major bleeds (3% with triple therapy, 1% with standard therapy).

 

COMMENT

 

Antithrombotic therapy use is predicated on prevention of ischemic events outweighing any increase in bleeding. These findings show that there are limits to combining multiple antithrombotic agents. In patients with a recent stroke or TIA, triple therapy had no demonstrable benefit for stroke prevention, and significant bleeding events occurred at an excess rate with triple therapy. Sometimes “less is more,” or at least better for the patient.

 

Seemant Chaturvedi, MD reviewing Bath PM et al. Lancet 2017 Dec 20.

 

CITATION(S):

Bath PM et al. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): A randomised, open-label, phase 3 superiority trial. Lancet 2017 Dec 20; [e-pub].

 

NEJM Journal Watch is produced by NEJM Group, a division of the Massachusetts Medical Society. Copyright ©2018 Massachusetts Medical Society. All rights reserved.

 

The above message comes from NEJM Journal Watch, who is solely responsible for its content.

Please reload

Featured Monthly Article
Recent News
Please reload

Please reload

Curt Wood, R.Ph., FASCP

Board Certified Geriatric Pharmacist

Elder Care Pharmacy Consultants take pride in being truly independent. Elder Care Pharmacy Consultants, LLC. has a comprehensive approach to antipsychotic use in order to help ensure nursing homes reach their goals, enhance star quality measures, and maintain federal and state compliance. Our success depends on your satisfaction with the services we provide..

The Consultant Pharmacist's Creed
 
I hold my patients' interest above all others.
 
I take responsibility for my patients' medication-related needs.
 
I ensure my patients' medications are the most appropriate, the most effective available, the safest possible, and are used correctly.
 
I identify, resolve and prevent medication-related problems that may interfere with the goals of therapy.

Address: 17566 Doe Run Rd.

               New London, MO 63459

 

Telephone : (573) 795 - 6351

Fax: (573) 985 - 3076
Email : curt@eldercarepharmacyconsultants.com

Copyright © Elder Care Pharmacy Consultants 2015

  • LinkedIn App Icon
  • Wix Twitter page
"Elder Care Pharmacy Consultants LLC., provides experienced clinical and regulatory pharmacy and consulting services relating to safe and effective medication use to skilled, assisted living, residential care nursing facilities." "Our mission is to provide pharmacy consulting services intended to optimize safe and effective medication use with the goal of helping skilled, assisted living and residential care nursing facilities provide the highest quality of care to achieve the best outcomes and maintain regulatory compliance."